MMI Co-Founder, John Hipp, PhD. to be Guest Editor for Special Issue of Bioengineering! Submit by May 30!
Press Release!: Driving Excellence in Cardiovascular Trials: MMI and Healthcare Inroads Deepen Collaboration
MMI VP of Client & Scientific Solutions, Elaine F. Chan, PhD, discusses lessons learned from OARSI 2026.
MMI and HCIR continue to expand their combined impact in cardiovascular clinical trials.
MMI Co-Founder and Chief Scientific Officer, Dr. John Hipp, PhD, has been invited to serve as the Guest Editor for an upcoming Special Issue of Bioengineering Journal!
US-based Medical Metrics, Inc. and Japan-based Micron, Inc. are teaming up to create a global imaging core lab offering for clinical trials.
The latest news regarding the 1st AI Platform to look at the dynamic nature of x-rays.
SpineCAMP can provide Actionable Insights related to spinal instability or fusion assessment!
Stop by to learn how SpineCAMP uses AI to analyze X-rays to generate enhanced visualizations & reports, to support clinical assessment of spine health.
https://tech.einnews.com/pr_news/659012865/medical-metrics-inc-hires-dennis-farrell-to-lead-commercialization-of-spinecamp-ai-powered-image-analysis-platform
https://www.einpresswire.com/article/656086444/medical-metrics-inc-announces-latest-510-k-clearance-for-spine-camp-ai-powered-image-analysis-platform
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
A newly signed law permits the FDA to clear a drug for human clinical trials while bypassing animal trials.
MMI co-founder, Dr. John Hipp, was recognized for his outstanding contributions to spine basic research.
